Accès ouvert
2025
article
OpenAlex
Vivek S. Purohit, Yeamin Huh, Martin E. Dowty, Anna Plotka et autres
Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine …
us, fr, in
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Xiaohong Sun, Wei Liu, Binyu Luo, Dongwei Ma et autres
For severe haemophilia A or B (factor VIII [FVIII] or IX [FIX] activity levels <1% of normal [<1 IU/dL]), the main prophylaxis treatment is standard clotting factor concentrates (CFCs). Limitations of CFCs include short half-life, frequent intravenous infusions and poor compliance.1 A …
cn, in, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Kei Fukuhara, Kenichi Furihata, Nobushige Matsuoka, Rio Itamura et autres
Abstract Vupanorsen (PF‐07285557) is a second‐generation tri‐N‐acetyl galactosamine (GalNAc3)‐antisense oligonucleotide targeted to angiopoietin‐like 3 (ANGPTL3) mRNA, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. To aid bringing innovative drugs to global patients efficiently, a multi‐purpose Japanese phase I study was …
jp, us, in
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Xiaoxing Wang, Vivek S. Purohit, Martin E. Dowty, David Rodrigues et autres
ABSTRACT Ritlecitinib, an inhibitor of Janus kinase 3 and hepatocellular carcinoma family kinases, is in development as potential treatment for several inflammatory diseases. In vitro studies presented ritlecitinib as an inhibitor of hepatic organic cation transporter (OCT) 1, renal transporters OCT2 and …
us, gb, in
(code pays fourni par la source)